Senores Pharmaceuticals Ltd
Senores Pharmaceuticals Ltd Q1 FY26 Results & Concall Highlights: Revenue, Margins & Order Book
Q1 FY26 earnings call: what management guided on revenue, margins and order book.
The short version
Senores Pharmaceuticals anticipates 20%-30% CAGR growth in U.S. Senores Pharmaceuticals expects a top-line growth of approximately 50% in FY26 over FY25.
From Senores Pharmaceuticals Ltd's Q1 FY26 earnings-call transcript · updated 23 Aug 2026.
Revenue & Sales Performance
- Senores Pharmaceuticals anticipates 20%-30% CAGR growth in U.S. regulated market revenue going forward.
- FY26 revenue guidance is around INR 600-650 crores, a 50% growth year-on-year, with 100% net profit growth.
- CDMO segment expected to contribute about INR 200 crores in FY26 with 20%-30% CAGR growth in subsequent years.
- Emerging markets show strong growth with 32% Y-o-Y revenue increase; EBITDA expected to improve from 6% to mid-teens (~10-15%) by next year.
- Product launches in H2 FY26 will further boost sales, with peak impact expected in FY27.
- Total US manufacturing capacity expansion will support volume growth, including four lines by end of the year.
- Inorganic growth through ANDA acquisitions (20+ acquisitions done) will add to product portfolio and sales.
- Emerging market new product registrations (719 under registration) will fuel future growth.
Profitability & Margins
See what Senores Pharmaceuticals Ltd said on profitability & margins — free account, 30 seconds.
Capital Expenditure Plans
- Current capex planned at around INR 100-150 crores for the year (FY26), down from earlier estimates of INR 250 crores.
- Capex split between US and India manufacturing facilities.
- In the US:
- - Four oral solid manufacturing lines planned, with the third line operational by Q3 FY26 and the fourth by year-end.
- - Expansion of US plant capacity from 1.2 billion to 2 billion units.
- India facility:
- - Strategic investment to cater to new markets (e.g., Brazil, Mexico, EU).
- Part of capex funding through internal accruals, part debt, and IPO proceeds.
- Some capex to spill into next year (around INR 50 crores).
- Focus on backward integration via API manufacturing facility in Chhatral (~100-150 metric tons capacity), filing DMF for FDA approval.
- Ongoing inorganic growth by acquiring ANDAs, with 20+ acquisitions so far, targeting product portfolio expansion aligned with business strategy.
Top-ranked in Pharmaceuticals & Biotechnology
Ranked on what management guided this quarter
Rank buckets describe management commentary on revenue and margin. Not investment advice, and not a forecast of returns.
Fundraising & Capital Structure
See what Senores Pharmaceuticals Ltd said on fundraising & capital structure — free account, 30 seconds.
Order Book & Pipeline
- Current CDMO-CMO order book stands at approximately USD 23 million as of the beginning of Q1FY26.
- The order book typically spans an execution timeframe of 12 to 18 months, with rolling and long-term contracts.
- The company maintains ongoing discussions with multiple partners, indicating potential for additional orders beyond the current book.
- Expected CDMO revenues for FY26 are around INR 200 crores, with growth visibility and confidence to meet this target.
- Future growth for CDMO-CMO is projected at a CAGR of 20% to 30%, with capacity additions underway to support pipeline expansion.
- Order book is considered firm but flexible, with some rollover and substitution of orders anticipated through the execution period.
Senores Pharmaceuticals Ltd — Quarterly revenue & net profit
Reported quarterly figures (₹ Cr). Latest: revenue ₹175 Cr, net profit ₹37 Cr. Revenue and profit are scaled separately — hover a quarter for exact figures.
Full financials →Continue your research
What Senores Pharmaceuticals Ltd's management said in earlier quarters
Others in Pharmaceuticals & Biotechnology this season
- Sai Life Sciences Ltd (Q1 FY26)
Sai Life Sciences reported a strong Q1 FY'26 with revenue up 77% YoY, driven mainly by CDMO (113% growth) and CRO (38% growth). Key concall takeaways from Sai…
- Cipla Ltd (Q1 FY26)
One Africa business grew 11% YoY, with continued focus on expansion. Key concall takeaways from Cipla's Q1 FY26 earnings call — and how it ranks against sector…
- Anthem Biosciences Ltd (Q1 FY26)
Capacity utilization in custom synthesis is around 70%, with expansions ongoing, indicating potential for further revenue growth. Key concall takeaways from…
- Akums Drugs & Pharmaceuticals Ltd (Q1 FY26)
300 crores linked to European markets. Key concall takeaways from Akums Drugs & Pharmaceuticals Ltd's Q1 FY26 earnings call — and how it ranks against sector…
Frequently Asked Questions
What were Senores Pharmaceuticals Ltd Q1 FY26 results?
Senores Pharmaceuticals anticipates 20%-30% CAGR growth in U.S. Senores Pharmaceuticals expects a top-line growth of approximately 50% in FY26 over FY25.
What is Senores Pharmaceuticals Ltd share price analysis?
Senores Pharmaceuticals Ltd currently shows a neutral. The stock trades at a P/E of 53.9 with a market cap of ₹6,805 Cr. Investors should review the full earnings analysis for detailed insights.
Is Senores Pharmaceuticals Ltd planning capital expenditure?
Current capex planned at around INR 100-150 crores for the year (FY26), down from earlier estimates of INR 250 crores.
Keep Senores Pharmaceuticals Ltd on your radar — track it to get its next earnings analysis in your feed.
This analysis is AI-generated based on publicly available earnings data and concall transcripts. This is not investment advice. Please consult a SEBI-registered advisor before making investment decisions.